Logo
x

Search

Subscribe Now

 US

Sumitomo Pharma’s Gemtesa (Vibegron) Secures the US FDA’s Approval to Treat Overactive Bladder (OAB) Symptoms in Men

Sumitomo Pharma’s Gemtesa (Vibegron) Secures the US FDA’s Approval to Treat Overactive Bladder (OAB) Symptoms in Men

  • December 25, 2024
Lantern Pharma's LP-184 Gains the US FDA’s Fast-Track Designation to Treat TNBC

Lantern Pharma's LP-184 Gains the US FDA’s Fast-Track Designation to Treat TNBC

  • December 19, 2024
New Drug Designations - October 2024

New Drug Designations - October 2024

  • November 26, 2024
Fresenius Kabi and Formycon Report the CHMP’s Positive Opinion of Ahzantive/Baiama/FYB203 (Biosimilar, Eylea)

Fresenius Kabi and Formycon Report the CHMP’s Positive Opinion of Ahzantive/Baiama/FYB203 (Biosimilar, Eylea)

  • November 18, 2024
Samsung Bioepis Report the CHMP’s Positive Opinion of Obodence & Xbryk (Biosimilar, Prolia & Xgeva)

Samsung Bioepis Report the CHMP’s Positive Opinion of Obodence & Xbryk (Biosimilar, Prolia & Xgeva)

  • November 15, 2024
ARTHEx Biotech Secures the US FDA’s Rare Pediatric Designation (RPD) to ATX-01 for Treating Myotonic Dystrophy Type 1 (DM1)

ARTHEx Biotech Secures the US FDA’s Rare Pediatric Designation (RPD) to ATX-01 for Treating Myotonic Dystrophy Type 1 (DM1)

  • November 7, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.